Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMandarin In.sg Regulatory News (MDO)

  • This share is currently suspended. It was suspended at a price of 1.65
  • There is currently no data for MDO

Publication of Prospectus

12 Mar 2015 09:42

RNS Number : 2694H
Mandarin Oriental International Ltd
12 March 2015
 



NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO CANADA, JAPAN, MALAYSIA, THE REPUBLIC OF SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL.

 

 

The following announcement was issued today to a Regulatory Information Service approved by the Financial Conduct Authority in the United Kingdom.

 

MANDARIN ORIENTAL INTERNATIONAL LIMITED

PUBLICATION OF PROSPECTUS

 

12th March 2015 - Further to the announcement by Mandarin Oriental International Limited (the 'Company') on Thursday, 5th March 2015 relating to the Rights Issue, the Company announces that the Prospectus in respect of the proposed Rights Issue was approved on Thursday, 12th March 2015 by the UK Listing Authority and has been published on the Company's website at http://www.mandarinoriental.com/investors/regulatory-announcements/.

 

A copy of the Prospectus has been submitted to the National Storage Mechanism and will be available for inspection at www.morningstar.co.uk/uk/nsm.

 

 

For further information, please contact:

 

Mandarin Oriental Hotel Group International Limited

Stuart Dickie (852) 2895 9288

J.P. Morgan Cazenove

Joint Corporate Broker

Ed Squire / Bronson Albery (44) 20 7742 4000

 

UBS

Joint Corporate Broker

Stuart Mackay (852) 2971 8888

David James (44) 20 7567 8421

 

 

THIS ANNOUNCEMENT IS AN ADVERTISEMENT AND DOES NOT CONSTITUTE A PROSPECTUS OR PROSPECTUS EQUIVALENT DOCUMENT. NOTHING IN THIS ANNOUNCEMENT SHOULD BE INTERPRETED AS A TERM OR CONDITION OF THE RIGHTS ISSUE. ANY DECISION TO PURCHASE, OTHERWISE ACQUIRE, SUBSCRIBE FOR, SELL OR OTHERWISE DISPOSE OF ANY NEW ORDINARY SHARES MUST BE MADE ONLY ON THE BASIS OF THE INFORMATION CONTAINED IN AND INCORPORATED BY REFERENCE INTO THE PROSPECTUS. COPIES OF THE PROSPECTUS WILL BE AVAILABLE ON PUBLICATION FROM THE OFFICE OF THE GROUP MANAGEMENT COMPANY, MANDARIN ORIENTAL HOTEL GROUP INTERNATIONAL LIMITED, AT 7TH FLOOR, 281 GLOUCESTER ROAD, CAUSEWAY BAY, HONG KONG AND ON THE COMPANY'S WEBSITE: WWW.MANDARINORIENTAL.COM/INVESTORS/REGULATORY-ANNOUNCEMENTS/.

 

J.P. Morgan Cazenove is authorized by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom. J.P. Morgan Cazenove is acting as corporate broker for the Company and is acting for no one else in connection with the Rights Issue and will not regard any other person as a client in relation to the Rights Issue and will not be responsible to anyone other than the Company for providing the protections afforded to its clients, or for providing advice in connection with the Rights Issue or any other matter, transaction or arrangement referred to in this announcement.

 

UBS is authorized and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom.  UBS is acting as corporate broker for the Company and is acting for no one else in connection with the Rights Issue and will not regard any other person as a client in relation to the Rights Issue and will not be responsible to anyone other than the Company for providing the protections afforded to its clients, or for providing advice in connection with the Rights Issue or any other matter, transaction or arrangement referred to in this announcement.

 

The Rights Issue is being underwritten by Jardine Strategic Holdings Limited ('Jardine Strategic').

 

This announcement has been issued by, and is the sole responsibility of, the Company. Apart from the responsibilities and liabilities, if any, which may be imposed on Jardine Strategic, J.P. Morgan Cazenove and UBS under the Financial Services and Markets Act 2000 or the regulatory regime established thereunder or any other applicable regulatory regime, none of Jardine Strategic, J.P. Morgan Cazenove or UBS accepts any responsibility or liability whatsoever and makes no representation or warranty, express or implied, in relation to the contents of this announcement, including its accuracy, completeness or verification or for any other statement made or purported to be made by them, or on their behalf, in connection with the Company, the Nil Paid Rights, the Nil Paid Rights Allocations, the New Ordinary Shares or the Rights Issue. Jardine Strategic, J.P. Morgan Cazenove and UBS accordingly disclaim, to the maximum extent permitted by law, all and any responsibility and liability, whether arising in tort, contract or otherwise, which they might otherwise be found to have in respect of this announcement or any such statement.

 

The information contained herein is restricted and is not for release, publication or distribution, directly or indirectly, in whole or in part in, into or from Canada, Japan, Malaysia, the Republic of South Africa, Switzerland, the United States (the 'Restricted Territories') or any other jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction. The securities to be issued in connection with the Rights Issue (the 'Securities') have not been and will not be registered under the securities laws of such jurisdictions and may not be offered, sold, taken up, exercised, resold, renounced, transferred or delivered, directly or indirectly, within such jurisdictions except pursuant to an exemption from and in compliance with any applicable securities laws.

 

This announcement is for information purposes only and does not constitute or form part of any offer to issue or sell, or the solicitation of an offer to acquire, purchase or subscribe for, any securities in any jurisdiction and should not be relied upon in connection with any decision to subscribe for or acquire any of the Securities. In particular, this announcement does not constitute or form part of any offer to issue or sell, or the solicitation of an offer to acquire, purchase or subscribe for, any securities in the Restricted Territories or any other jurisdiction in which such an offer or solicitation would be unlawful.

 

Certain statements, beliefs and opinions in this document are forward-looking, which reflect the Company's or, as appropriate, the Company's directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. Forward-looking statements contained in this document regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. You should not place undue reliance on forward-looking statements, which speak only as of the date of this announcement.

 

This announcement and the information contained herein does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The Securities have not been and will not be registered under the US Securities Act of 1933 (the 'Securities Act'), and may not be offered or sold in or into the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. The Securities will not be registered under or offered in compliance with applicable securities laws of any state, province, territory, county or jurisdiction of the United States or the other Restricted Territories. Accordingly, unless an exemption under the relevant securities law is applicable, the Securities may not be offered, sold, taken up, exercised, renounced, resold, delivered or distributed, directly or indirectly, in or into the United States or the other Restricted Territories or any other jurisdiction if to do so would constitute a violation of the relevant laws of, or require registration thereof in, such jurisdiction. There will be no public offering of the Securities in the United States.

 

 

- end -

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
PDIPKBDNCBKKFND
Date   Source Headline
19th Jan 20261:45 pmRNSCompletion of Acquisition by Jardine Strategic
16th Jan 20267:00 amRNSCourt Sanction of Scheme of Arrangement
9th Jan 20269:19 amRNSOCB Dividend
31st Dec 20257:22 amRNSUpdate on OCB Sale and Acquisition Timeline
31st Dec 20257:22 amRNSUpdate on OCB Sale and Acquisition Timeline
8th Dec 20253:47 pmRNSResults of Court Meeting & Special General Meeting
21st Nov 20259:58 amRNSInterim Management Statement
14th Nov 202511:37 amRNSReplacement: Publication of Shareholder Circular
14th Nov 20259:38 amRNSAnnouncement (Publication of Shareholder Circular)
17th Oct 202510:24 amRNSRecommended Cash Acquisition of Mandarin Oriental
17th Oct 202510:21 amRNSSale of 301,555 sq.ft. of One Causeway Bay
2nd Oct 202510:20 amRNSDividend Declaration
30th Sep 20257:00 amRNSRESPONSE TO MEDIA SPECULATION
25th Sep 202510:23 amRNSBlock listing Interim Review
28th Jul 202512:33 pmRNSHalf-year Results
11th Jul 202510:28 amRNSNotification to Untraced Shareholders
15th May 202511:44 amRNSINTERIM MANAGEMENT STATEMENT
2nd May 20251:02 pmRNSResult of AGM
30th Apr 202510:24 amRNSDividend Declaration
7th Apr 202510:39 amRNSAnnual Financial Report
25th Mar 20259:20 amRNSBlock listing Interim Review
5th Mar 20251:42 pmRNS2024 PRELIMINARY RESULTS
14th Nov 20249:43 amRNSINTERIM MANAGEMENT STATEMENT
4th Nov 20249:22 amRNSDirectorate Change
2nd Oct 202410:26 amRNSDividend Declaration
25th Sep 202410:19 amRNSBlock listing Interim Review
31st Jul 202410:17 amRNSCompany Board Change
24th Jul 20243:06 pmRNSHalf-year Report
16th Jul 202410:49 amRNSCompany Board Changes
12th Jun 202411:59 amRNSDisposal
23rd May 202410:44 amRNSINTERIM MANAGEMENT STATEMENT
8th May 202412:38 pmRNSResult of AGM
2nd May 202410:23 amRNSDividend Declaration
9th Apr 202410:28 amRNSAnnual Financial Report
25th Mar 20249:26 amRNSBLOCK LISTING INTERIM REVIEW
7th Mar 202410:04 amRNS2023 Preliminary Results
1st Mar 20249:25 amRNSCHANGE OF SINGAPORE BRANCH REGISTRAR
22nd Dec 20231:18 pmRNSMO Signs Option to sell MO, Paris
24th Nov 20239:22 amRNSDirectorate Change
9th Nov 20239:54 amRNSINTERIM MANAGEMENT STATEMENT
27th Sep 202310:28 amRNSDividend Declaration
25th Sep 202310:33 amRNSBlock listing Interim Review
1st Sep 202310:27 amRNSDirector Declaration
28th Jul 202310:33 amRNSHalf-year Results
18th May 202310:23 amRNSInterim Management Statement
4th May 202312:31 pmRNSResult of AGM
2nd May 202310:17 amRNSDirectorate Change
3rd Apr 202310:26 amRNSAnnual Financial Report
31st Mar 202310:24 amRNSTotal Voting Rights
27th Mar 202310:30 amRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.